| Name |
Seminar |
| Sh. Ashok Kumar, Chairman-NPPA |
A Perspective on Regulation for Control, Pricing & Availability of Drugs in India |
| Sh Arun Jha, Member Secretary-NPPA |
Teasers or Pointers |
| Dr Anban Pillay, Cluster Manager, Health Economics,Ministry of Health, South Africa |
Pharmaceutical Pricing The South African Experience |
| Charles Clift, Access to Medicines Health Services Team, DFID |
Debates on UK Pricing Policy Are they relevant to India |
S.Srinivasan “Chinu”
LOCOST, Baroda, India |
Current & Emerging Options for Price Regulations |
| D G Shah , Indian Pharmaceutical Alliance |
Issues and Options for Price Regulation Industry Perspectiv |
| Panos Kanavos, London School of Economics |
Price regulation models in Turkey and the Russian Federation1 ,2 |
| Leena Menghaney, MSF |
Price control and patented drugs |
Michael Borowitz
Policy and Research Division, DFID |
DFID approach to Access to Medicines |
| Richard Laing, World Health Organization, Geneva |
Overview of Global Pricing and Availability |
| Rakesh Basant, IIM, Ahmedabad |
Drug Price Control in Developing Countries |
| Sudip Chaudhuri, Professor of Economics Indian Institute of Management Calcutta |
Pharmaceutical Prices and India |
Dr. Krisantha Weerasuriya
WHO – South-East Asia Region |
Regulatory Pricing and Regulatory Framework for Affordable Medicines |
| Prashant Yadav, MIT |
Regulatory Pricing and Regulatory Framework for Affordable Medicines |
| Roy Atkinson |
Linking Drug Pricing with Pharmaceutical Patents in Canada |
